NASDAQ:ALPN

Alpine Immune Sciences (ALPN) Stock Forecast, Price & News

$11.70

0.00 (0.00%)

(As of 09:45 AM ET)

Compare

Today's Range: $11.57
▼
$11.76
50-Day Range: $11.52
▼
$13.98
52-Week Range: $4.82
▼
$14.92

Volume: 6,296 shs
Average Volume: 159,900 shs
Market Capitalization: $575.64 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $18.00

Alpine Immune Sciences MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 53.8% Upside
$18.00 Price Target
Short Interest: Bearish
5.33% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.18) to ($1.47) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.84 out of 5 stars

Medical Sector

815th out of 975 stocks

Pharmaceutical Preparations Industry

385th out of 459 stocks

3.5

Analyst's Opinion

Consensus Rating
Alpine Immune Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $18.00, Alpine Immune Sciences has a forecasted upside of 53.8% from its current price of $11.70.
Amount of Analyst Coverage
Alpine Immune Sciences has only been the subject of 3 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
5.33% of the outstanding shares of Alpine Immune Sciences have been sold short.
Short Interest Ratio / Days to Cover
Alpine Immune Sciences has a short interest ratio ("days to cover") of 11.3, which indicates bearish sentiment.
Change versus previous month
Short interest in Alpine Immune Sciences has recently increased by 3.97%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Alpine Immune Sciences does not currently pay a dividend.
Dividend Growth
Alpine Immune Sciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ALPN.

2.7

News and Social Media Coverage

News Sentiment
Alpine Immune Sciences has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Alpine Immune Sciences this week, compared to 1 article on an average week.
MarketBeat Follows
1 people have added Alpine Immune Sciences to their MarketBeat watchlist in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Alpine Immune Sciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
42.30% of the stock of Alpine Immune Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
75.17% of the stock of Alpine Immune Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Alpine Immune Sciences are expected to decrease in the coming year, from ($1.18) to ($1.47) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Alpine Immune Sciences is -8.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Alpine Immune Sciences is -8.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Alpine Immune Sciences has a P/B Ratio of 3.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Alpine Immune Sciences (NASDAQ:ALPN) Stock

Alpine Immune Sciences, Inc. operates as a clinical-stage immunotherapy company. It focuses on creating various immunotherapies through protein engineering technologies for autoimmune and inflammatory diseases. The company has strategic collaborations with biopharmaceutical companies and has a pipeline of clinical and preclinical candidates in development. Its pipeline includes Povetacicept, a dual B cell cytokine antagonist for multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways for treatment of severe inflammatory diseases. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

ALPN Price History

30 days | 90 days | 365 days | Advanced Chart

ALPN Stock News Headlines

September 20, 2023 | msn.com

Here's Why You Should Invest in Alpine (ALPN) Stock Now

September 13, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Alpine Immune Sciences (ALPN)

September 28, 2023 | Wall Street Fundamentals (Ad)

Would Buffett Approve of This Growth Strategy?

Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.

September 12, 2023 | finance.yahoo.com

Alpine Immune Sciences Presents First Preclinical Data for Povetacicept in Myasthenia Gravis at the American Neurological Association Annual Meeting

September 5, 2023 | finance.yahoo.com

Alpine Immune Sciences to Present First Preclinical Data for Povetacicept in Myasthenia Gravis at the American Neurological Association Annual Meeting

August 31, 2023 | markets.businessinsider.com

Analyst Expectations for Alpine Immune Sciences's Future

August 31, 2023 | msn.com

Alpine Immune Sciences (ALPN) Price Target Increased by 10.67% to 16.93

August 30, 2023 | finance.yahoo.com

Alpine Immune Sciences Announces Initiation of Dosing in 240 mg IgA Nephropathy Cohort of Povetacicept Clinical Study (RUBY-3)

September 28, 2023 | Edge On The Street (Ad)

The Strategic Gold Play You Haven't Heard About

Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.

August 24, 2023 | finance.yahoo.com

Alpine Immune Sciences, Inc. (ALPN) Is a Great Choice for 'Trend' Investors, Here's Why

August 22, 2023 | finance.yahoo.com

Alpine Immune Sciences Announces Appointment of M. Christina Yi as Chief Technology Officer and Grant under Nasdaq Listing Rule 5635(c)

August 17, 2023 | finance.yahoo.com

Does Alpine Immune Sciences, Inc. (ALPN) Have the Potential to Rally 25.38% as Wall Street Analysts Expect?

August 16, 2023 | msn.com

Alpine Immune Sciences: Going Strong But For How Long?

August 16, 2023 | finance.yahoo.com

Companies Like Alpine Immune Sciences (NASDAQ:ALPN) Are In A Position To Invest In Growth

August 15, 2023 | msn.com

HC Wainwright & Co. Maintains Alpine Immune Sciences (ALPN) Buy Recommendation

August 15, 2023 | msn.com

Wedbush Maintains Alpine Immune Sciences (ALPN) Outperform Recommendation

August 14, 2023 | finance.yahoo.com

Alpine Immune Sciences Reports Second Quarter 2023 Financial Results

July 23, 2023 | finance.yahoo.com

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) surges 14%; private equity firms who own 38% shares profited along with institutions

June 22, 2023 | finance.yahoo.com

Alpine Immune (ALPN) Stock Up 19% MTD, Will the Uptick Continue?

June 14, 2023 | markets.businessinsider.com

Alpine Immune Sciences (ALPN) Receives a Rating Update from a Top Analyst

June 10, 2023 | fool.com

Alpine Immune Sciences (NASDAQ: ALPN)

May 19, 2023 | finance.yahoo.com

Alpine Immune Sciences to Present Data from RUBY-1, a Phase 1 Study of Povetacicept, at Upcoming Scientific Congresses

May 13, 2023 | msn.com

Alpine Immune Sciences GAAP EPS of -$0.28 beats by $0.09, revenue of $9.4M beats by $2.52M

May 12, 2023 | msn.com

HC Wainwright & Co. Reiterates Alpine Immune Sciences (ALPN) Buy Recommendation

May 11, 2023 | msn.com

Recap: Alpine Immune Sciences Q1 Earnings

May 11, 2023 | finance.yahoo.com

Alpine Immune Sciences Reports First Quarter 2023 Financial Results

May 5, 2023 | finance.yahoo.com

Pinning Down Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) P/S Is Difficult Right Now

See More Headlines

Receive ALPN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alpine Immune Sciences and its competitors with MarketBeat's FREE daily newsletter.

ALPN Company Calendar

Last Earnings: 8/14/2023
Today: 9/28/2023
Next Earnings (Estimated): 11/13/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ALPN
CUSIP: N/A
CIK: 1626199
Web: www.alpineimmunesciences.com
Phone: (206) 788-4545
Fax: 303-440-8399
Employees: 126
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $18.00
High Stock Price Forecast: $22.00
Low Stock Price Forecast: $15.00
Forecasted Upside/Downside: +53.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.38)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-57,760,000.00
Net Margins: -201.07%
Pretax Margin: -199.19%
Return on Equity: -33.44%
Return on Assets: -21.43%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.88
Quick Ratio: 3.88

Sales & Book Value

Annual Sales: $30.06 million
Price / Sales: 19.15
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.90 per share
Price / Book: 3.00

Miscellaneous

Outstanding Shares: 49,200,000
Free Float: 28,390,000
Market Cap: $575.64 million
Optionable: Not Optionable
Beta: 1.27

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Dr. Mitchell H. Gold M.D. (Age 55)
Exec. Chairman & CEO
Comp: $778.2k

Dr. Stanford Peng M.D. (Age 52)
Ph.D., Pres and Head of R&D
Comp: $751.2k

Mr. Paul Rickey (Age 44)
Sr. VP, CFO, Treasurer & Sec.
Comp: $577.1k

Dr. Wayne R. Gombotz (Age 64)
Chief Technology Officer

Temre Johnson
Head of IR & Corp. Communications

Dr. Remy Durand Ph.D. (Age 38)
Chief Bus. Officer

Dr. Andrew Seth Sandler M.D. (Age 58)
Chief Medical Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ALPN Stock - Frequently Asked Questions

Should I buy or sell Alpine Immune Sciences stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ALPN shares.
View ALPN analyst ratings or view top-rated stocks.
What is Alpine Immune Sciences' stock price forecast for 2023?: 5 analysts have issued 12 month price targets for Alpine Immune Sciences' shares. Their ALPN share price forecasts range from $15.00 to $22.00. On average, they predict the company's stock price to reach $18.00 in the next twelve months. This suggests a possible upside of 53.8% from the stock's current price.
View analysts price targets for ALPN or view top-rated stocks among Wall Street analysts.
How have ALPN shares performed in 2023?: Alpine Immune Sciences' stock was trading at $7.35 on January 1st, 2023. Since then, ALPN shares have increased by 59.2% and is now trading at $11.70.
View the best growth stocks for 2023 here.
When is Alpine Immune Sciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our ALPN earnings forecast.
How were Alpine Immune Sciences' earnings last quarter?: Alpine Immune Sciences, Inc. (NASDAQ:ALPN) announced its quarterly earnings results on Monday, August, 14th. The biotechnology company reported ($0.27) EPS for the quarter, beating analysts' consensus estimates of ($0.38) by $0.11. The biotechnology company earned $8.59 million during the quarter, compared to analysts' expectations of $8.08 million. Alpine Immune Sciences had a negative trailing twelve-month return on equity of 33.44% and a negative net margin of 201.07%.
What ETF holds Alpine Immune Sciences' stock ?: AdvisorShares Dorsey Wright Micro-Cap ETF holds 2,351 shares of ALPN stock, representing 0.65% of its portfolio.

What other stocks do shareholders of Alpine Immune Sciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Alpine Immune Sciences investors own include Viking Therapeutics (VKTX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Abeona Therapeutics (ABEO), CymaBay Therapeutics (CBAY), Genocea Biosciences (GNCA), OPKO Health (OPK), SCYNEXIS (SCYX), Energy Transfer (ET) and Palatin Technologies (PTN).
What is Alpine Immune Sciences' stock symbol?: Alpine Immune Sciences trades on the NASDAQ under the ticker symbol "ALPN."
Who are Alpine Immune Sciences' major shareholders?: Alpine Immune Sciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include RA Capital Management L.P. (9.78%), Great Point Partners LLC (7.01%), BlackRock Inc. (4.76%), Geode Capital Management LLC (1.29%), State Street Corp (1.19%) and Renaissance Technologies LLC (0.67%). Insiders that own company stock include Decheng Capital China Life Sci, Life Sciences Viii L Frazier, Mitchell Gold, Orbimed Advisors Llc, Robert E Conway and Robert E Conway.
View institutional ownership trends.
How do I buy shares of Alpine Immune Sciences?: Shares of ALPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Alpine Immune Sciences' stock price today?: One share of ALPN stock can currently be purchased for approximately $11.70.
How much money does Alpine Immune Sciences make?: Alpine Immune Sciences (NASDAQ:ALPN) has a market capitalization of $575.64 million and generates $30.06 million in revenue each year. The biotechnology company earns $-57,760,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis.
How many employees does Alpine Immune Sciences have?: The company employs 126 workers across the globe.
How can I contact Alpine Immune Sciences?: Alpine Immune Sciences' mailing address is 188 East Blaine Street Suite 200, Seattle WA, 98102. The official website for the company is www.alpineimmunesciences.com. The biotechnology company can be reached via phone at (206) 788-4545, via email at laurence@gilmartinir.com, or via fax at 303-440-8399.

This page (NASDAQ:ALPN) was last updated on 9/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial